Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark
This article was originally published in The Pink Sheet Daily
Portfolio includes Phase II candidate GRC 6211 for treatment of pain conditions, including osteoarthritic pain.
You may also be interested in...
Extension of existing collaboration with Pfizer will fund Renovis’ research in the area through June 30, 2008.
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.